Case Report Nutrition Psychology
Association between tranexamic acid and chronic pain scores: evidence from pregnant women

Association between tranexamic acid and chronic pain scores: evidence from pregnant women

Authors

Sarah Andersen

Sarah Andersen

Hamad Medical Corporation, Tunisia

Aisha Silva

Aisha Silva

Royal Melbourne Hospital, Saint-Barthelemy

Yusuf Patel

Yusuf Patel

Hamad Medical Corporation, Jersey

James Zhang

James Zhang

King Fahad Medical City, Iceland

Corresponding
Layla Mensah

Layla Mensah

American University of Beirut Medical Center, Italy

Published

October 9, 2025

Paper ID

PAP-000062

Status

Published

DOI

10.65712/tmj.test000320

Association between tranexamic acid and chronic pain scores: evidence from pregnant women

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around tranexamic acid varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.79 (95% CI 0.32 to 0.63). Conclusion: These findings suggest that tranexamic acid is associated with better chronic pain scores in pregnant women.

Introduction

Guidelines make only a weak recommendation on tranexamic acid. Earlier studies of tranexamic acid were small or single-centre.

Guidelines make only a weak recommendation on tranexamic acid. Earlier studies of tranexamic acid were small or single-centre.

Practice around tranexamic acid varies widely between centres. The cost of chronic pain scores to health systems is substantial.

Practice around tranexamic acid varies widely between centres. chronic pain scores remains a leading cause of avoidable harm among pregnant women. Guidelines make only a weak recommendation on tranexamic acid.

Discussion

These findings suggest that tranexamic acid is associated with better chronic pain scores in pregnant women. Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded. Future work should test tranexamic acid in a pragmatic multicentre trial.

Future work should test tranexamic acid in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.

Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. Future work should test tranexamic acid in a pragmatic multicentre trial.

Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. These findings suggest that tranexamic acid is associated with better chronic pain scores in pregnant women.

Residual confounding cannot be excluded. These findings suggest that tranexamic acid is associated with better chronic pain scores in pregnant women. Implementation will depend on staffing, cost and local protocols.

Conclusions

Tranexamic acid is a reasonable option for pregnant women to improve chronic pain scores.

References

1. Nakamura N, Kim C, et al. Continuous glucose monitoring and length of stay. Crit Care Med. 2010;267(4):626-1006.

2. Osei D, Rahman F, et al. High-flow nasal oxygen and chronic pain scores. Lancet. 2022;59(7):418-1695.

3. Mueller V, Nakamura F, et al. Continuous glucose monitoring and 30-day readmission. Pediatrics. 2009;13(7):262-1610.

4. Haddad D, Herrera T, et al. Frailty screening and ventilator-free days. Diabetes Care. 2015;150(6):725-1478.

5. Ahmed H, Nakamura T, et al. Early enteral nutrition and length of stay. Ann Intern Med. 2010;397(3):65-1658.

6. Haddad P, Volkov Z, et al. Point-of-care ultrasound and patient satisfaction. Diabetes Care. 2010;147(4):202-1717.

Appendices

Supplementary tables are available on request.

Materials and Methods

Eligible participants were pregnant women. Analyses were adjusted for age, sex and baseline severity. The primary outcome was chronic pain scores, assessed blind to allocation.

Analyses were adjusted for age, sex and baseline severity. The primary outcome was chronic pain scores, assessed blind to allocation.

Missing data were handled with multiple imputation. Eligible participants were pregnant women. Analyses were adjusted for age, sex and baseline severity. The primary outcome was chronic pain scores, assessed blind to allocation.

Results

The adjusted odds ratio was 0.57 (95% CI 0.28 to 0.65). chronic pain scores occurred in 8% of the intervention group versus 38% of controls. Serious adverse events were rare and similar between groups.

GroupnEvents
Age ≥ 651939
Centre A31315
Centre A60354
Control5990
TABLE 1: Baseline characteristics
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Kaplan–Meier curve for chronic pain scores
Shown for pregnant women; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Distribution of chronic pain scores
Shown for pregnant women; error bars are 95% confidence intervals.

3423 participants were included (median age 41 years). Serious adverse events were rare and similar between groups.

chronic pain scores occurred in 10% of the intervention group versus 38% of controls. Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.